• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Novo Nordisk doubles stock of Wegovy starter doses but supply constraints persist: CEO

cafead

Administrator
Staff member
  • cafead   Jan 31, 2024 at 12:12: PM
via Even with a competitor’s drug now on the scene, Novo Nordisk is aiming for another year of dominance in the obesity arena thanks in large part to a resupply of starter doses of the company’s weight-loss blockbuster Wegovy.

article source
 

<